Session 3G: Treating Heart Failure by Inhibiting PLCB-1 in Rat Ventricular Cardiomyocytes
Session Number
Session 3G: 4th Presentation
Advisor(s)
J. Andrew Wasserstrom, Northwestern University
Location
Room A117
Start Date
28-4-2017 1:15 PM
End Date
28-4-2017 2:30 PM
Abstract
One of the most prevalent chronic heart diseases in the United States, heart failure is the process wherein heart muscles slowly function worse until the heart fails. Many believe heart failure is caused by the loss of the T-tubule structures which are attacked as a result of the activation of PLCB-1. We are looking to find a compound which will prevent the activation of PLCB-1. We used auto TT analysis in order to examine the effectiveness of Compound 4 (C4) in cardiomyocytes treated with C4. We used a confocal microscope to image treated and untreated cells to see T-tubule structural integrity levels. However, the results indicate that C4 requires further testing since it does not seem to produce a sensible dose-response curve.
Session 3G: Treating Heart Failure by Inhibiting PLCB-1 in Rat Ventricular Cardiomyocytes
Room A117
One of the most prevalent chronic heart diseases in the United States, heart failure is the process wherein heart muscles slowly function worse until the heart fails. Many believe heart failure is caused by the loss of the T-tubule structures which are attacked as a result of the activation of PLCB-1. We are looking to find a compound which will prevent the activation of PLCB-1. We used auto TT analysis in order to examine the effectiveness of Compound 4 (C4) in cardiomyocytes treated with C4. We used a confocal microscope to image treated and untreated cells to see T-tubule structural integrity levels. However, the results indicate that C4 requires further testing since it does not seem to produce a sensible dose-response curve.